Literature DB >> 19186352

HIV seropositivity predicts longer duration of stay and rehospitalization among nonbacteremic febrile injection drug users with skin and soft tissue infections.

Yu-Hsiang Hsieh1, Richard E Rothman, John G Bartlett, Samual Yang, Gabor D Kelen.   

Abstract

BACKGROUND: Skin/soft tissue infections (SSTIs) are the leading cause of hospital admissions among injection drug users (IDUs).
METHODS: We performed a retrospective investigation to determine the epidemiology of SSTIs (ie, cellulitis and/or abscesses) in febrile IDUs, with a focus on bacteriology and potential predictors of increased health care utilization measured by longer length of stay and rehospitalization. Subjects were drawn from a cohort of febrile IDUs presenting to an inner-city emergency department from 1998 to 2004.
RESULTS: Of the 295 febrile IDUs with SSTIs, specific discharge diagnoses were cellulitis only (n = 143, 48.5%), abscesses only (n = 113, 38.3%), and both (n = 39, 13.2%). Documented HIV infection rate was 28%. Of note, 10 subjects were newly diagnosed with HIV infection during their visits. Staphylococcus aureus was the leading pathogen, and increasing rates of methicillin-resistant S. aureus emerged over time (before 2001: 4%, 2001-2004: 56%, P < 0.01). HIV seropositivity predicted rehospitalization within 90 days [adjusted hazard ratios and 95% confidence intervals: 2.90 (1.20 to 7.02)]. HIV seropositivity also predicted increased length of stay in those who were nonbacteremic [adjusted hazard ratios and 95% confidence intervals: 1.49 (1.11 to 2.01)].
CONCLUSIONS: Among febrile IDUs with SSTIs, a strong association between HIV seropositivity and health care resource utilization was found. Accordingly, attention to HIV serostatus should be considered in clinical disposition decisions for this vulnerable high-risk population.

Entities:  

Mesh:

Year:  2008        PMID: 19186352     DOI: 10.1097/qai.0b013e318183ac84

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  7 in total

1.  Evaluation of the Centers for Disease Control and Prevention Recommendations for Hepatitis C Virus Testing in an Urban Emergency Department.

Authors:  Yu-Hsiang Hsieh; Richard E Rothman; Oliver B Laeyendecker; Gabor D Kelen; Ama Avornu; Eshan U Patel; Jim Kim; Risha Irvin; David L Thomas; Thomas C Quinn
Journal:  Clin Infect Dis       Date:  2016-02-21       Impact factor: 9.079

2.  Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in U.S. hospital discharge records: a cross-sectional study.

Authors:  Mehdi Nouraie; Sergei Nekhai; Victor R Gordeuk
Journal:  Sex Transm Infect       Date:  2012-05-24       Impact factor: 3.519

3.  Skin and needle hygiene intervention for injection drug users: results from a randomized, controlled Stage I pilot trial.

Authors:  Kristina T Phillips; Michael D Stein; Bradley J Anderson; Karen F Corsi
Journal:  J Subst Abuse Treat       Date:  2012-02-14

4.  Thirty-day Readmission Rates in an HIV-infected Cohort From Rio de Janeiro, Brazil.

Authors:  Lara E Coelho; Sayonara R Ribeiro; Andre M Japiassu; Ronaldo I Moreira; Priscila C Lara; Valdilea G Veloso; Beatriz Grinsztejn; Paula M Luz
Journal:  J Acquir Immune Defic Syndr       Date:  2017-08-01       Impact factor: 3.731

Review 5.  Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs.

Authors:  Frederick L Altice; Adeeba Kamarulzaman; Vincent V Soriano; Mauro Schechter; Gerald H Friedland
Journal:  Lancet       Date:  2010-07-31       Impact factor: 79.321

6.  Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: what is the impact of CD4 counts and HAART use?

Authors:  Nancy F Crum-Cianflone; Greg Grandits; Sara Echols; Anuradha Ganesan; Michael Landrum; Amy Weintrob; Robert Barthel; Brian Agan
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

7.  Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis.

Authors:  Nathan Ford; Gabriela Patten; Ajay Rangaraj; Mary-Ann Davies; Graeme Meintjes; Tom Ellman
Journal:  Lancet HIV       Date:  2022-03       Impact factor: 12.767

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.